Top

Published in:

Open Access 01-12-2023 | Type 1 Diabetes | Review

Autoantibody test for type 1 diabetes in children: are there reasons to implement a screening program in the general population? A statement endorsed by the Italian Society for Paediatric Endocrinology and Diabetes (SIEDP-ISPED) and the Italian Society of Paediatrics (SIP)

Authors: Valentino Cherubini, Francesco Chiarelli

Published in: Italian Journal of Pediatrics | Issue 1/2023

Abstract

In recent years screening of type 1 diabetes (T1D) in both at risk children and general population has been widely discussed with the aim of increasing awareness of the importance to early detect (and possibly treat) at-risk children in early stages of the chronic autoimmune progression to T1D.

In fact, it is well known that first-degree relatives have the highest risk of T1D, but up to 90% of children who develop T1D do not have a family history and belong to the general population.

The reasons for screening children well before the clinical onset of T1D include prevention of DKA (still up to 60% children are diagnosed with DKA) and related morbidities and mortality, reducing the need for hospitalisation, time to provide emotional support and education to ensure a smooth transition to insulin treatment, and opportunities for new treatments to prevent or delay progression.

There are pros and cons of screening of T1D in children, but recent evidences suggest that it is now time to consider possible a screening for T1D in children.

Recently, the European Society for Paediatric Endocrinology (ESPE) has endorsed a Position Statement, discussing the pros and cons of screening for T1D in the general population; ESPE supports national Societies for Paediatric Endocrinology to spread information on this important issue in various countries throughout Europe; the Italian Society for Paediatric Endocrinology and Diabetes (SIEDP-ISPED) and the Italian Society of Paediatrics (SIP) endorse this document with the specific aim of increasing awareness on screening for paediatric T1D in the general population.

Available only for authorised users

Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2001;358:221–9.PubMedCrossRef

Patterson CC, Harjutsalo V, Rosenbauer J, Neu A, Cinek O, Skrivarhaug T, et al. Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 european centres in the 25 year period 1989–2013: a multicentre prospective registration study. Diabetologia. 2019;62:408–17.PubMedCrossRef

Sussman M, Benner J, Haller MJ, Rewers M, Griffiths R. Estimated Lifetime Economic Burden of type 1 diabetes. Diabetes Technol Ther. 2020;22:121–30.PubMedCrossRef

Cherubini V, Gesuita R, Bonfanti R, Franzese A, Frongia AP, Iafusco D, Iannilli A, Lombardo F, Rabbone I, Sabbion A, Salvatoni A, Scaramuzza A, Schiaffini R, Sulli N, Toni S, Tumini S, Mosca A, Carle F, VIPKIDS Study Group. (Health-related quality of life and treatment preferences in adolescents with type 1 diabetes. The VIPKIDS study. Acta Diabetol. 2014;51:43–51.PubMedCrossRef

Birkebaek NH, Kamrath C, Grimsmann JM, Aakesson K, Cherubini V, Dovc K, et al. Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 national diabetes registries. Lancet Diabetes Endocrinol. 2022;10:786–94.PubMedPubMedCentralCrossRef

Dhatariya KK, Glaser NS, Codner E, Umpierrez GE. Diabetic ketoacidosis. Nat Rev Dis Prim. 2020;6:1–20.

Duca LM, Wang B, Rewers M, Rewers A. Diabetic ketoacidosis at diagnosis of type 1 diabetes predicts poor long-term glycemic control. Diabetes Care. 2017;40:1249–55.PubMedCrossRef

Desai D, Mehta D, Mathias P, Menon G, Schubart UK. Health care utilization and burden of diabetic ketoacidosis in the U.S. over the past decade: a nationwide analysis. Diabetes Care. 2018;41:1631–8.PubMedCrossRef

Aye T, Mazaika PK, Mauras N, Marzelli MJ, Shen H, Hershey T, et al. Impact of early diabetic ketoacidosis on the developing brain. Diabetes Care. 2019;42:443–9.PubMedCrossRef

10.

Cherubini V, Marino M, Carle F, Zagaroli L, Bowers R, Gesuita R. Effectiveness of ketoacidosis prevention campaigns at diagnosis of type 1 diabetes in children: A systematic review and meta-analysis [Internet]. Vol. 175. Salesi Hospital, Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona Umberto I G M, Lancisi G, Salesi. Department of Women’s and Children’s Health, via Corridoni, 11, Ancona, 60123, Italy; 2021. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85105577648&doi=10.1016%2Fj.diabres.2021.108838&partnerID=40&md5=1a828e071d8d6d4e3fae23426810a818

11.

Ziegler AG, Kick K, Bonifacio E, Haupt F, Hippich M, Dunstheimer D, et al. Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany. JAMA - J Am Med Assoc. 2020;323:339–51.CrossRef

12.

Angus VC, Waugh N. Hospital admission patterns subsequent to diagnosis of type 1 diabetes in children: a systematic review. BMC Health Serv Res. 2007;7(Iddm):1–10.

13.

Maahs DM, Hermann JM, Holman N, Foster NC, Kapellen TM, Allgrove J, et al. Rates of diabetic ketoacidosis: international comparison with 49,859 pediatric patients with type 1 diabetes from England, Wales, the U.S., Austria, and Germany. Diabetes Care. 2015;38:1876–82.PubMedCrossRef

14.

Reynolds KA, Helgeson VS. Children with diabetes compared to peers: Depressed? Distressed? A meta-analytic review. Ann Behav Med. 2011;42:29–41.PubMedCrossRef

15.

Care D, Suppl SS. Children and adolescents: Standards of medical care in diabetes- 2020. Diabetes Care. 2020;43:163–82.CrossRef

16.

Markowitz JT, Volkening LK, Butler DA, Antisdel-Lomaglio J, Anderson BJ, Laffel LMB. Re-examining a measure of diabetes-related burden in parents of young people with type 1 diabetes: the Problem Areas in diabetes survey - parent revised version (PAID-PR). Diabet Med. 2012;29:526–30.PubMedPubMedCentralCrossRef

17.

Prigge R, McKnight JA, Wild SH, Haynes A, Jones TW, Davis EA, et al. International comparison of glycaemic control in people with type 1 diabetes: an update and extension. Diabet Med. 2022;39:1–12.CrossRef

18.

Abraham MB, Jones TW, Naranjo D, Karges B, Oduwole A, Tauschmann M, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes. 2018;19:178–92.PubMedCrossRef

19.

Cryer PE. Mechanisms of Hypoglycemia-Associated Autonomic failure in diabetes. N Engl J Med. 2013;369:362–72.PubMedCrossRef

20.

Insel RA, Dunne JL, Ziegler AG. General population screening for type 1 diabetes: has its time come? Curr Opin Endocrinol Diabetes Obes. 2015;22:270–6.PubMedCrossRef

21.

Axon WEA. A year’s use of the ’ency-clopæedia britannica.’. Library (Lond). 1912;s3-III(10):221–9.

22.

Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309:2473–9.PubMedPubMedCentralCrossRef

23.

Mahon JL, Sosenko JM, Rafkin-Mervis L, Krause-Steinrauf H, Lachin JM, Thompson C, et al. The TrialNet natural history study of the development of type 1 diabetes: objectives, design, and initial results. Pediatr Diabetes. 2009;10:97–104.PubMedCrossRef

24.

Besser REJ, Ng SM, Gregory JW, Dayan CM, Randell T, Barrett T. General population screening for childhood type 1 diabetes: is it time for a UK strategy? Arch Dis Child. 2022;107:790–5.PubMedCrossRef

25.

Cherubini V, Marino M, Scaramuzza AE, Tiberi V, Bobbio A, Delvecchio M, et al. The Silent Epidemic of Diabetic ketoacidosis at diagnosis of type 1 diabetes in children and adolescents in Italy during the COVID-19 pandemic in 2020. Front Endocrinol. 2022;13:1–9.

26.

Samuelsson U, Steineck I, Gubbjornsdottir S. A high mean-HbA1c value 3-15months after diagnosis of type 1 diabetes in childhood is related to metabolic control, macroalbuminuria, and retinopathy in early adulthood-a pilot study using two nation-wide population based quality registries. Pediatr Diabetes. 2014;15:229–35.PubMedCrossRef

27.

Shalitin S, Phillip M. Which factors predict glycemic control in children diagnosed with type 1 diabetes before 6.5 years of age? Acta Diabetol. 2012;49:355–62.PubMedCrossRef

28.

Viswanathan V, Sneeringer MR, Miller A, Eugster EA, DiMeglio LA. The utility of hemoglobin A1c at diagnosis for prediction of future glycemic control in children with type 1 diabetes. Diabetes Res Clin Pract. 2011;92(1):65–8.PubMedPubMedCentralCrossRef

29.

McQueen RB, Rasmussen CG, Waugh K, Frohnert BI, Steck AK, Yu L, et al. Cost and cost-effectiveness of large-scale screening for type 1 diabetes in Colorado. Diabetes Care. 2020;43:1496–503.PubMedPubMedCentralCrossRef

30.

Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, et al. An Anti-CD3 antibody, Teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019;381:603–13.PubMedPubMedCentralCrossRef

31.

Dayan CM, Korah M, Tatovic D, Bundy BN, Herold KC. Changing the landscape for type 1 diabetes: the first step to prevention. Lancet. 2019;394(10205):1286–96.PubMedCrossRef

32.

Wilhelm-Benartzi CS, Miller SE, Bruggraber S, Picton D, Wilson M, Gatley K, et al. Study protocol: minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes. BMJ Open. 2021;11:1–24.CrossRef

33.

Hummel M, Ziegler AG, Roth R. Psychological impact of childhood islet autoantibody testing in families participating in the BABYDIAB study. Diabet Med. 2004;21:324–8.PubMedCrossRef

34.

Meehan C, Fout B, Ashcraft J, Schatz DA, Haller MJ. Screening for T1D risk to reduce DKA is not economically viable. Pediatr Diabetes. 2015;16:565–72.PubMedCrossRef

35.

Raab J, Haupt F, Scholz M, Matzke C, Warncke K, Lange K, et al. Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. BMJ Open. 2016;6:1–12.CrossRef

36.

Ziegler AG, Hoffmann GF, Hasford J, Larsson HE, Danne T, Berner R, et al. Screening for asymptomatic β-cell autoimmunity in young children. Lancet Child Adolesc Health. 2019;3:288–90.PubMedCrossRef

37.

Chiarelli F, Rewers M, Phillip M. Screening of islet autoantibodies for children in the general population: a position statement endorsed by the European Society for Paediatric Endocrinology. Horm Res Paediatr. 2022;95:393–6.PubMedCrossRef

38.

Sims EK, Besser REJ, Dayan C, Rasmussen CG, Greenbaum C, Griffin KJ, et al. Screening for type 1 diabetes in the General Population: a Status Report and Perspective. Diabetes. 2022;71(4):610–23.PubMedPubMedCentralCrossRef

Title: Autoantibody test for type 1 diabetes in children: are there reasons to implement a screening program in the general population? A statement endorsed by the Italian Society for Paediatric Endocrinology and Diabetes (SIEDP-ISPED) and the Italian Society of Paediatrics (SIP)
Authors: Valentino Cherubini
Francesco Chiarelli
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Type 1 Diabetes
Hypoglycemia
Pediatrics
Insulins
Insulins
Type 1 Diabetes in Children
Published in: Italian Journal of Pediatrics / Issue 1/2023
Electronic ISSN: 1824-7288
DOI: https://doi.org/10.1186/s13052-023-01438-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Autoantibody test for type 1 diabetes in children: are there reasons to implement a screening program in the general population? A statement endorsed by the Italian Society for Paediatric Endocrinology and Diabetes (SIEDP-ISPED) and the Italian Society of Paediatrics (SIP)

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

Report and follow-up on two new patients with congenital mesoblastic nephroma

Role of luteinizing hormone urinary levels in the diagnostic and therapeutic management of female central precocious puberty

A pediatric case of Chlamydia psittaci caused severe Acute Respiratory Distress Syndrome (ARDS) in Italy

The impact of gender medicine on neonatology: the disadvantage of being male: a narrative review

Autoimmune adrenal insufficiency in children: a hint for polyglandular syndrome type 2?

Genotypic and phenotypic heterogeneity among Chinese pediatric genetic white matter disorders